Literature DB >> 21536327

Comparative analysis of binding affinities to epidermal growth factor receptor of monoclonal antibodies nimotuzumab and cetuximab using different experimental animal models.

N Ledón1, A Casacó, E Casanova, I Beausoleil.   

Abstract

Although pharmaco/toxicological studies have always been conducted in pharmacologically relevant species in which the test material is pharmacologically active, the very specificity of many biopharmaceuticals could present challenges in the identification of a relevant species for pharmaco/toxicological studies. Alternative approaches may improve the predictive value of preclinical assessments of species-specific biopharmaceuticals. This could lead to improved decision-making, reduce the number of experimental animals by eliminating non-relevant studies, and decrease the time and cost involved in the drug development process. As an alternative to utilizing traditional animal models, this study investigated the activity of human EGF and the anti-EGF receptor monoclonal antibodies nimotuzumab and cetuximab using the placenta microsomal fraction of different experimental animals. Ligand-receptor binding curves were obtained from the different experimental animal models, and binding constants were calculated based on the Scatchard plots. The constants for human and monkey EGF receptor expressed on the placental extract showed a K(a)<10(-8)M, while rabbits, mice and rats showed a K(a)>10(-8)M. The K(a) values obtained from animal placentas show that Macaca fascicularis and Cercopitecus aethiops monkeys are relevant species for studying the pharmaco/toxicological properties of nimotuzumab and cetuximab.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21536327     DOI: 10.1016/j.placenta.2011.04.008

Source DB:  PubMed          Journal:  Placenta        ISSN: 0143-4004            Impact factor:   3.481


  4 in total

1.  Small sized EGFR1 and HER2 specific bifunctional antibody for targeted cancer therapy.

Authors:  Li Ding; Caiping Tian; Song Feng; Guissi Fida; Congying Zhang; Yuxiang Ma; Guanhua Ai; Samuel Achilefu; Yueqing Gu
Journal:  Theranostics       Date:  2015-01-21       Impact factor: 11.556

2.  Efficacy of aerosol therapy of lung cancer correlates with EGFR paralysis induced by AvidinOX-anchored biotinylated Cetuximab.

Authors:  Rita De Santis; Antonio Rosi; Anna Maria Anastasi; Caterina Chiapparino; Claudio Albertoni; Barbara Leoni; Angela Pelliccia; Daniela Santapaola; Valeria Carollo; Emanuele Marra; Luigi Aurisicchio; Brunilde Arseni; Maria Lucrezia Pacello; Gabriella Palmieri; Simone Battella; Fiorella Petronzelli; Ferdinando Maria Milazzo
Journal:  Oncotarget       Date:  2014-10-15

3.  Evaluating the efficacy of the anticancer drug cetuximab by atomic force microscopy.

Authors:  Qingrong Zhang; Yan Shi; Haijiao Xu; Lulu Zhou; Jing Gao; Junguang Jiang; Mingjun Cai; Yuping Shan
Journal:  RSC Adv       Date:  2018-06-13       Impact factor: 4.036

4.  EGFR targeting monoclonal antibody combines with an mTOR inhibitor and potentiates tumor inhibition by acting on complementary signaling hubs.

Authors:  Roshan James; Siddharth Vishwakarma; Indira V Chivukula; Chetana Basavaraj; Ramakrishnan Melarkode; Enrique Montero; Pradip Nair
Journal:  Cancer Med       Date:  2012-08-01       Impact factor: 4.452

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.